Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715347 | 0.86 | EGLN1 (0.46) | EGLN1EGLN3CYP1A2CYP2C9HPGD | |
| SCHEMBL6716946 | 0.81 | EGLN1 (0.47) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6672468 | 0.81 | EGLN1 (0.51) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6197455 | 0.80 | NR3C1 (0.44) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6196625 | 0.78 | NR3C1 (0.44) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6668933 | 0.76 | KCNH2 (0.52) | EGLN1POLA1 | |
| SCHEMBL6669425 | 0.76 | MAPK1 (0.45) | EGLN1 | |
| SCHEMBL6334722 | 0.75 | ABCB1 (0.45) | EGLN1EGLN3CYP1A2CYP2C9HPGD | |
| SCHEMBL6286358 | 0.75 | ABCB1 (0.41) | ABCB1 | |
| SCHEMBL6286392 | 0.75 | GAA (0.45) | HPGDABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | claimed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | claimed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| US-6730682-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2004-05-04 | — | — | US | disclosed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | EGLN1 1486/4885EGLN3 461/4885CYP1A2 2118/4885 |
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | EGLN1 134/4885EGLN3 257/4885CYP1A2 1665/4885 |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | EGLN1 134/4885EGLN3 257/4885CYP1A2 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.